Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.72 |
| ▸ | CNR1 | P21554 | 3/20 | 0.51 |
| ▸ | HTR4 | Q13639 | 11/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323199 | 0.94 | CNR2 (0.68) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| SCHEMBL13578361 | 0.85 | CNR2 (0.98) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| SCHEMBL13578360 | 0.83 | CNR2 (1.00) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4327097 | 0.80 | CNR2 (0.88) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4322918 | 0.79 | CNR2 (0.90) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| SCHEMBL4327335 | 0.78 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL13578366 | 0.78 | CNR2 (0.70) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| SCHEMBL4318453 | 0.76 | CNR2 (0.59) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| SCHEMBL4326041 | 0.76 | CNR2 (0.46) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| SCHEMBL4327358 | 0.76 | CNR2 (0.64) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885HTR4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.